题名 | ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. |
链接 | http://jco.ascopubs.org/content/20/9/2240.long |
欢迎光临 科研速递论坛 (http://expaper.cn/) | Powered by Discuz! X2.5 |